Cell2Cure has got a EU-grant to develop a new global market for stem cells.
The PRO-SCT project will advance a strong commercial and operational position for Cell2Cure to develop a new global market for donor stem cells. To do this properly and successfully, the grant of EU-Instrument phase I is of immense importance.
The ambition of Cell2Cure is to be first on the market with an industrialized production platform for growing adipose tissue derived stem cells from healthy donors. This will provide ready-to-use stem cells whenever and wherever needed on a global scale.
Today stem cell treatment typically involve a process where the patient’s own cells are grown for approximately 6-8 weeks, before the patient can be treated with his/her own stem cells. Not only is the time an issue, it is also a costly procedure to prepare stem cells for one patient at a time.
Compared to treating a patient with their own stem cells, Cell2Cure donor-stem cells allows for scalability and easy distribution thereby improving availability and reducing both cost and time needed for stem cells treatments.
The Cell2Cure technology and products are already used in large and approved clinical trials in the heart disease area – compliant with all regulatory frameworks in six European countries. Initial clinical trials have shown, that C2C stem cells are safe, applicable in the clinic and have promising clinical effects for patients with heart failure.
The overall ambition of C2C is to make stem cells play a therapeutic role in a variety of diseases, and then even more patients will benefit from stem cell based treatments.